<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77113">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01703845</url>
  </required_header>
  <id_info>
    <org_study_id>1237.24</org_study_id>
    <nct_id>NCT01703845</nct_id>
  </id_info>
  <brief_title>A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.</brief_title>
  <official_title>A Randomised, Open-label, Parallel-group Trial to Assess Pharmacokinetics and Safety of Tiotropium + Olodaterol Fixed-dose Combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) Delivered by the RESPIMAT Inhaler After 3 Weeks Once Daily Treatment in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol
      fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3
      weeks once daily treatment in Japanese patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum measured concentration in plasma at steady state (Cmax,ss)</measure>
    <time_frame>15 min pre-dose and 5, 10, 20, 40 min, 1, 2, 3, and 4 hours following drug administration on day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in plasma over the time interval t1 to t2 at steady state (AUCt1 t2,ss)</measure>
    <time_frame>15 min pre-dose and 5, 10, 20, 40 min, 1, 2, 3, and 4 hours following drug administration on day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point at steady state (AUC0-tz,ss)</measure>
    <time_frame>15 min pre-dose and 5, 10, 20, 40 min, 1, 2, 3, and 4 hours following drug administration on day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from dosing to the maximum concentration in plasma at steady state (tmax,ss)</measure>
    <time_frame>day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount that is eliminated in urine from the time point t1 to time point t2 at steady state (Aet1-t2,ss)</measure>
    <time_frame>from 0 to 2 and 2 to 4 hours following drug administration on day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction eliminated in urine from the time point t1 to time point t2 at steady state (fet1-t2,ss)</measure>
    <time_frame>from 0 to 2 and 2 to 4 hours following drug administration on day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance from the time point t1 until the time point t2 at steady state (CLR,t1-t2,ss)</measure>
    <time_frame>from 0 to 2 and 2 to 4 hours following drug administration on day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (including assessment based on physical examination, vital signs, laboratory evaluations,  ECG)</measure>
    <time_frame>up to 6 weeks post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium + Olodaterol (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium + Olodaterol (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium and Olodaterol  fixed dose combination (FDC) solution for inhalation - RESPIMAT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium (high dose) + Olodaterol</intervention_name>
    <description>Tiotropium + Olodaterol solution for inhalation</description>
    <arm_group_label>Tiotropium + Olodaterol (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium (low dose) + Olodaterol</intervention_name>
    <description>Tiotropium + Olodaterol solution for inhalation</description>
    <arm_group_label>Tiotropium + Olodaterol (low dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease

          2. Relatively stable airway obstruction with post FEV1=&lt;30% of predicted normal and&lt; 80%
             predicted normal and post FEV1/FVC &lt;70%

          3. Male or female Japanese patients, 40 years of age or older

          4. Smoking history of more than 10 pack  years

        Exclusion criteria:

          1. Significant disease other than COPD

          2. Clinically relevant abnormal lab values

          3. History of asthma

          4. Diagnosis of thyrotoxicosis

          5. Diagnosis of paroxysmal tachycardia

          6. A marked baseline prolongation of QT/QTc interval

          7. A history of additional risk factors for Torsade de Pointes (TdP)

          8. History of myocardial infarction within 1 year of screening visit

          9. Unstable or life-threatening cardiac arrhythmia

         10. Hospitalization for heart failure within the past year

         11. Known active tuberculosis

         12. Malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         13. History of life-threatening pulmonary obstruction

         14. History of cystic fibrosis

         15. Clinically evident bronchiectasis

         16. History of significant alcohol or drug abuse

         17. Thoracotomy with pulmonary resection

         18. Oral ß-adrenergics

         19. Oral corticosteroid medication at unstable doses

         20. Regular use of daytime oxygen therapy for more than one hour per day

         21. Pulmonary rehabilitation program in the six weeks prior to the screening visit

         22. Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

         23. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA

         24. Pregnant or nursing women

         25. Women of childbearing potential not using a highly effective method of birth control

         26. Patients who have previously been randomized in this study or are currently
             participating in another study

         27. Patients who are unable to comply with pulmonary medication restrictions

         28. Patients with narrow-angle glaucoma or micturition disorder due to prostatic
             hyperplasia etc

         29. Patients being treated with medications that prolong the QT/QTc interval
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1237.24.24001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toshima-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 13, 2013</lastchanged_date>
  <firstreceived_date>October 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tiotropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
